Importantly, indirect targeting of the molecules within the KRAS signaling pathway also proved to be almost ineffective due to the complexity and biological heterogeneity of KRAS mutations in NSCLC [68, 70]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.